Projects

RNDr. Dana Cholujová, PhD.

International

Finished
  • Multiple myeloma intra-clonal heterogeneity: evolution and implications of targeted therapy
    Program: ERANET
    Duration: 1. 7. 2016 – 31. 7. 2020
  • Arsenic in cancer treatment: mechanism of action and new forms of delivery
    Program: Inter-academic agreement
    Duration: 1. 1. 2011 – 31. 12. 2013

National

Current
  • Clonal and immune interactions in high-grade transformation of B-cell lymphomas
    Program: SRDA
    Duration: 1. 7. 2024 – 30. 6. 2027
  • Characterization of NF-kB signaling by defining the anti-myeloma activity and mechanisms of action of QNZ inhibitor
    Program: VEGA
    Duration: 1. 1. 2023 – 31. 12. 2025
Finished
  • Harnessing the immunological mechanisms in various subtypes of B cell lymphoma
    Program: SRDA
    Duration: 1. 7. 2020 – 30. 6. 2024
  • Anti-myeloma activity by composite realgar nanomaterials and its mechanism in vitro and in vivo
    Program: VEGA
    Duration: 1. 1. 2020 – 31. 12. 2022
  • Development of novel diagnostic and predictive high-dimensional immunophenotyping tool for hematological malignancies
    Program: Other projects
    Duration: 1. 11. 2019 – 31. 12. 2022
  • Assessment of immune checkpoints in B cell malignancies
    Program: VEGA
    Duration: 1. 1. 2020 – 31. 12. 2022
  • Identification of biomarkers associated with late toxicity of chemotherapy in testicular germ cell tumors.
    Program: SRDA
    Duration: 1. 7. 2016 – 30. 6. 2020
  • The impact of tumor microenvironment and therapy on subclonal diversity in MM and WM
    Program: VEGA
    Duration: 1. 1. 2017 – 31. 12. 2019
  • Chemoenzymatic synthesis and evaluation of biological activities of natural glycophenolics and their analogues
    Program: SRDA
    Duration: 1. 10. 2013 – 30. 9. 2017
  • Role of microenvironment and B-cell immunity in the spontaneous regression of MM patients undergoing hight dose therapy and autologous stem cell transplantation
    Program: SRDA
    Duration: 1. 10. 2013 – 30. 6. 2017
  • Study of exosome production and the impact of chemotherapeutics on their properties
    Program: VEGA
    Duration: 1. 1. 2013 – 31. 12. 2016
  • Targeted Augmented Cellular Therapy against Tumor Initiating and Chemoresistant Cells
    Program: SRDA
    Duration: 1. 7. 2012 – 31. 12. 2015
  • Anticancer effects of isothiocyanates and their combination with other therapeutic approaches.
    Program: VEGA
    Duration: 1. 1. 2011 – 31. 12. 2014
  • Implementation of radiobiological research of intensity-modulated proton therapy into clinical oncology practice
    Program: EU Structural Funds Research & Development
    Duration: 20. 10. 2010 – 31. 3. 2014
  • Cisplatin resistance in human ovarian cancer cells and its modulation by signaling pathway- and nuclear transcription factor NF kappa-B inhibition
    Program: VEGA
    Duration: 1. 1. 2010 – 31. 12. 2012
  • Epithelial-mesenchymal transition in the model of breast carcinoma stem cells in vitro
    Program: SRDA
    Duration: 1. 3. 2006 – 1. 3. 2009
  • Monitoring of immunological parameters of multiple myeloma patients during course of Biobran consumption
    Program: Other projects
    Duration: 1. 1. 2005 – 31. 12. 2008
  • Role of activated stromal fibroblasts in regulation of progression haematopoietic malignancies
    Program: VEGA
    Duration: 1. 1. 2006 – 31. 12. 2008
Employees